Carbon Tetrachloride (CCl4

Published date04 November 2020
Citation85 FR 70147
Record Number2020-24478
SectionNotices
CourtEnvironmental Protection Agency
Federal Register, Volume 85 Issue 214 (Wednesday, November 4, 2020)
[Federal Register Volume 85, Number 214 (Wednesday, November 4, 2020)]
                [Notices]
                [Pages 70147-70149]
                From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
                [FR Doc No: 2020-24478]
                -----------------------------------------------------------------------
                ENVIRONMENTAL PROTECTION AGENCY
                [EPA-HQ-OPPT-2019-0499; FRL-10015-51]
                Carbon Tetrachloride (CCl4); Final Toxic Substances Control Act
                (TSCA) Risk Evaluation; Notice of Availability
                AGENCY: Environmental Protection Agency (EPA).
                ACTION: Notice.
                -----------------------------------------------------------------------
                SUMMARY: The Environmental Protection Agency (EPA) is announcing the
                availability of the final Toxic Substances Control Act (TSCA) risk
                evaluation of Carbon Tetrachloride (CCl4). The purpose of
                conducting risk evaluations under TSCA is to determine whether a
                chemical substance presents an unreasonable risk of injury to health or
                the environment under the conditions of use, including an unreasonable
                risk to a relevant potentially exposed or susceptible subpopulation,
                without consideration of
                [[Page 70148]]
                costs or other nonrisk factors. EPA has determined that specific
                conditions of use of CCl4 present an unreasonable risk of
                injury to health or the environment. For those conditions of use for
                which EPA has found an unreasonable risk, EPA must take regulatory
                action to address that unreasonable risk through risk management
                measures enumerated in TSCA. EPA has also determined that specific
                conditions of use do not present unreasonable risk of injury to health
                or the environment. For those conditions of use for which EPA has found
                no unreasonable risk to health or the environment, the Agency's
                determination is a final Agency action and is issued via order in the
                risk evaluation.
                ADDRESSES: The docket for this action, identified by docket
                identification (ID) number EPA-HQ-OPPT-2019-0499, is available online
                at http://www.regulations.gov or in-person at the Office of Pollution
                Prevention and Toxics Docket (OPPT Docket), Environmental Protection
                Agency Docket Center (EPA/DC), West William Jefferson Clinton Bldg.,
                Rm. 3334, 1301 Constitution Ave. NW, Washington, DC. The Public Reading
                Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday,
                excluding legal holidays. The telephone number for the Public Reading
                Room is (202) 566-1744, and the telephone number for the OPPT Docket is
                (202) 566-0280.
                 Due to the public health concerns related to COVID-19, the EPA
                Docket Center (EPA/DC) and Public Reading Room are closed to visitors
                with limited exceptions. The EPA/DC staff continue to provide remote
                customer service via email, phone, and webform. For the latest status
                information on EPA/DC services and docket access, visit https://www.epa.gov/dockets.
                FOR FURTHER INFORMATION CONTACT:
                 For technical information contact: Dr. Karen Eisenreich, Office of
                Pollution Prevention and Toxics (7403M), Environmental Protection
                Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460-0001; telephone
                number: (202) 564-7843; email address: [email protected].
                 For general information contact: The TSCA-Hotline, ABVI-Goodwill,
                422 South Clinton Ave., Rochester, NY 14620; telephone number: (202)
                554-1404; email address: [email protected].
                SUPPLEMENTARY INFORMATION:
                I. General Information
                A. Does this action apply to me?
                 This action is directed to the public in general. This action may
                be of interest to persons who are or may be interested in risk
                evaluations of chemical substances under TSCA, 15 U.S.C. 2601 et seq.
                Since other entities may also be interested in this final risk
                evaluation, the EPA has not attempted to describe all the specific
                entities that may be affected by this action.
                B. What is EPA's authority for taking this action?
                 TSCA section 6, 15 U.S.C. 2605, requires EPA to conduct risk
                evaluations to ``determine whether a chemical substance presents an
                unreasonable risk of injury to health or the environment, without
                consideration of costs or other nonrisk factors, including an
                unreasonable risk to a potentially exposed or susceptible subpopulation
                identified as relevant to the risk evaluation by the Administrator,
                under the conditions of use.'' 15 U.S.C. 2605(b)(4)(A). TSCA sections
                6(b)(4)(A) through (H) enumerate the deadlines and minimum requirements
                applicable to this process, including provisions that provide
                instruction on chemical substances that must undergo evaluation, the
                minimum components of a TSCA risk evaluation, and the timelines for
                public comment and completion of the risk evaluation. TSCA also
                requires that EPA operate in a manner that is consistent with the best
                available science, make decisions based on the weight of the scientific
                evidence and consider reasonably available information. 15 U.S.C.
                2625(h), (i), and (k). TSCA section 6(i) directs that a determination
                of ``no unreasonable risk'' shall be issued by order and considered to
                be a final Agency action, while a determination of ``unreasonable
                risk'' is not considered to be a final Agency action. 15 U.S.C.
                2605(i).
                 The statute identifies the minimum components for all chemical
                substance risk evaluations. For each risk evaluation, EPA must publish
                a document that outlines the scope of the risk evaluation to be
                conducted, which includes the hazards, exposures, conditions of use,
                and the potentially exposed or susceptible subpopulations that EPA
                expects to consider. 15 U.S.C. 2605(b)(4)(D). The statute further
                provides that each risk evaluation must also: (1) Integrate and assess
                available information on hazards and exposures for the conditions of
                use of the chemical substance, including information that is relevant
                to specific risks of injury to health or the environment and
                information on relevant potentially exposed or susceptible
                subpopulations; (2) describe whether aggregate or sentinel exposures
                were considered and the basis for that consideration; (3) take into
                account, where relevant, the likely duration, intensity, frequency, and
                number of exposures under the conditions of use; and (4) describe the
                weight of the scientific evidence for the identified hazards and
                exposures. 15 U.S.C. 2605(b)(4)(F)(i) through (ii) and (iv) through
                (v). Each risk evaluation must not consider costs or other nonrisk
                factors. 15 U.S.C. 2605(b)(4)(F)(iii).
                 The statute requires that the risk evaluation process be completed
                within a specified timeframe and provide an opportunity for public
                comment on a draft risk evaluation prior to publishing a final risk
                evaluation. 15 U.S.C. 2605(b)(4).
                 Subsection 5.4.1 of the final risk evaluation for CCl4
                constitutes the order required under TSCA section 6(i)(1), and the ``no
                unreasonable risk'' determinations in that subsection are considered to
                be a final Agency action effective on the date of issuance of the
                order. In conducting risk evaluations, ``EPA will determine whether the
                chemical substance presents an unreasonable risk of injury to health or
                the environment under each condition of use within the scope of the
                risk evaluation . . . .'' 40 CFR 702.47. Under EPA's implementing
                regulations, ``[a] determination by EPA that the chemical substance,
                under one or more of the conditions of use within the scope of the risk
                evaluation, does not present an unreasonable risk of injury to health
                or the environment will be issued by order and considered to be a final
                Agency action, effective on the date of issuance of the order.'' 40 CFR
                702.49(d). For purposes of TSCA section 19(a)(1)(A), the date of
                issuance of the TSCA section 6(i)(1) order for CCl4 shall be
                at 1:00 p.m. Eastern time (standard or daylight, as appropriate) on the
                date that is two weeks after the date when this notice is published in
                the Federal Register, which is in accordance with 40 CFR 23.5.
                C. What action is EPA taking?
                 EPA is announcing the availability of the risk evaluation of the
                chemical substance identified in Unit II. In this risk evaluation EPA
                has made unreasonable risk determinations on some of the conditions of
                use within the scope of the risk evaluation for this chemical. For
                those conditions of use for which EPA has found an unreasonable risk of
                injury to health or the environment, EPA must initiate regulatory
                action to address those risks
                [[Page 70149]]
                through risk management measures enumerated in 15 U.S.C. 2605(a).
                 EPA also is announcing the availability of the information required
                to be provided publicly with each risk evaluation, which is available
                online at http://www.regulations.gov in the dockets identified. 40 CFR
                702.51. Specifically, EPA has provided:
                 The scope document and problem formulation (in Docket ID
                No. EPA-HQ-OPPT-2016-0733);
                 Draft risk evaluation, and final risk evaluation (in
                Docket ID No. EPA-HQ-OPPT-2019-0499);
                 All notices, determinations, findings, consent agreements,
                and orders (in Docket ID No. EPA-HQ-OPPT-2019-0499);
                 Any information required to be provided to the Agency
                under 15 U.S.C. 2603 (in Docket ID No. EPA-HQ-OPPT-2016-0733 and Docket
                ID No. EPA-HQ-OPPT-2019-0499);
                 A nontechnical summary of the risk evaluation (in Docket
                ID No. EPA-HQ-OPPT-2019-0499);
                 A list of the studies, with the results of the studies,
                considered in carrying out each risk evaluation (Risk Evaluation for
                Carbon Tetrachloride (CCl4)) in Docket ID No. EPA-HQ-OPPT-
                2019-0499);
                 The final peer review report, including the response to
                peer review and public comments received during peer review (in Docket
                ID No. EPA-HQ-OPPT-2019-0499); and
                 Response to public comments received on the draft scope
                and the draft risk evaluation (in Docket ID No. EPA-HQ-OPPT-2019-0499).
                II. TSCA Risk Evaluation
                A. What is EPA's risk evaluation process for existing chemicals under
                TSCA?
                 The risk evaluation process is the second step in EPA's existing
                chemical review process under TSCA, following prioritization and before
                risk management. As this chemical is one of the first ten chemical
                substances undergoing risk evaluation, the chemical substance was not
                required to go through prioritization (81 FR 91927, December 19, 2016)
                (FRL-9956-47). The purpose of conducting risk evaluations is to
                determine whether a chemical substance presents an unreasonable risk of
                injury to health or the environment under the conditions of use,
                including an unreasonable risk to a relevant potentially exposed or
                susceptible subpopulation. As part of this process, EPA must evaluate
                both hazard and exposure, not consider costs or other nonrisk factors,
                use reasonably available information and approaches in a manner that is
                consistent with the requirements in TSCA for the use of the best
                available science, and ensure decisions are based on the weight of the
                scientific evidence.
                 The specific risk evaluation process that EPA has established by
                rule to implement the statutory process is set out in 40 CFR part 702
                and summarized on EPA's website at http://www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-evaluations-existing-chemicals-under-tsca. As explained in the preamble to EPA's final rule on
                procedures for risk evaluation (82 FR 33726, July 20, 2017) (FRL-9964-
                38), the specific regulatory process set out in 40 CFR part 702,
                subpart B is being followed for the first ten chemical substances
                undergoing risk evaluation to the maximum extent practicable.
                 Prior to the publication of this final risk evaluation, a draft
                risk evaluation was subject to peer review and public comment. EPA
                reviewed the report from the peer review committee and public comments
                and has amended the risk evaluation in response to these comments as
                appropriate. The public comments, peer review report, and EPA's
                response to comments is in Docket ID No. EPA-HQ-OPPT-2019-0499. Prior
                to the publication of the draft risk evaluation, EPA made available the
                scope and problem formulation, and solicited public input on uses and
                exposure. EPA's documents and the public comments are in Docket ID No.
                EPA-HQ-OPPT-2016-0733. Additionally, information about the scope,
                problem formulation, and draft risk evaluation phases of the TSCA risk
                evaluation for this chemical is available at EPA's website at https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-evaluation-carbon-tetrachloride.
                B. What is carbon tetrachloride (CCl4)?
                 Carbon tetrachloride (CCl4) is used as a feedstock in
                the production of hydrochloro fluorocarbons (HCFCs), hydrofluorocarbons
                (HFCs) and hydrofluoroolefins (HFOs), and is a high-production volume
                solvent. It is also used as a process agent in the manufacturing of
                petrochemicals-derived and agricultural products and other chlorinated
                compounds such as chlorinated paraffins, chlorinated rubber and others
                that may be used downstream in the formulation of solvents for
                degreasing and cleaning, adhesives, sealants, paints, coatings, rubber,
                cement and asphalt formulations.
                 Authority: 15 U.S.C. 2601 et seq.
                Andrew Wheeler,
                Administrator.
                [FR Doc. 2020-24478 Filed 11-3-20; 8:45 am]
                BILLING CODE 6560-50-P
                

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT